Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Prognostic role of E2F1 gene expression in human cancer: a meta-analysis

Authors: Jingjing Li, Wen Bi, Fang Lu, Bei Pan, Mengqiu Xiong, Lubanga Nasifu, Zhenlin Nie, Bangshun He

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Objective

E2F1 has been confirmed to be highly expressed in a variety of cancers. To better understand the prognostic value of E2F1 in cancer patients, this study was conducted to comprehensively evaluate the prognostic value of E2F1 in cancer according to published data.

Method

PubMed, Web of Science and CNKI database were searched until May 31th, 2022 by using key words to retrieve the published essays on the role of E2F1 expression in the prognostic value of cancer. The essays were identified according to the inclusion and exclusion criteria. The pooled result of hazard ratio and 95% confidence interval was calculated with Stata17.0 software.

Result

A total of 17 articles were included in this study involved in 4481 cancer patients. The pooled results showed that higher E2F1 expression was significantly correlated with unfavorable overall survival (HR = 1.10, I2 = 95.3%, *PHeterogeneity = 0.000) and disease-free survival (HR = 1.41, I2 = 95.2%, *PHeterogeneity = 0.000) of cancer patients. Such a significant association of was maintained subgroup of sample size of patients (> 150: for OS, HR = 1.77, and for DFS, HR = 0.91; or < 150: for OS, HR = 1.93, and for DFS, HR = 4.39), ethnicity (Asian: for OS, HR = 1.65, and for DFS, HR = 1.08; or not Asian: HR = 3.55, and for DFS, HR = 2.87), the data from database (clinical: for OS, HR = 1.24, and for DFS, HR = 1.40; or database: for OS, HR = 2.29, and for DFS, HR = 3.09), paper published year (after 2014: for OS, HR = 1.90;and for DFS,HR = 1.87; or before 2014: for OS, HR = 1.40, and for DFS, HR = 1.22); cancer type (female specific cancer: for OS, HR = 1.41, and for DFS, HR = 0.64; or non-gender specific cancers: for OS, HR = 2.00, and for DFS, HR = 2.95). In addition, according to the database data, we also found that higher E2F1 expression level would lead to worse prognosis of patients, and the results were consistent with the statistical analysis results in the paper.

Conclusion

E2F1 could be served as a prognostic biomarker in cancer patients and higher levels of in cancer patients could predict shorter overall survival and disease-free survival.
Appendix
Available only for authorised users
Literature
1.
Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM, et al. Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. J Clin Invest. 2017;127(3):830–42.CrossRefPubMedPubMedCentral
2.
Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326–38.CrossRefPubMed
3.
Emanuele MJ, Enrico TP, Mouery RD, Wasserman D, Nachum S, Tzur A. Complex Cartography: Regulation of E2F Transcription Factors by Cyclin F and Ubiquitin. Trends Cell Biol. 2020;30(8):640–52.CrossRefPubMedPubMedCentral
4.
Han Z, Mo R, Cai S, Feng Y, Tang Z, Ye J, Liu R, Cai Z, Zhu X, Deng Y, et al. Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer. Front Cell Dev Biol. 2022;10:831329.CrossRefPubMedPubMedCentral
5.
Fang ZJ, Lin M, Li CX, Liu H, Gong CJ. A comprehensive review of the roles of E2F1 in colon cancer. Am J Cancer Res. 2020;10(3):757–68.PubMedPubMedCentral
6.
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O’Donovan M, Correll CU, Kane JM, van Os J, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.CrossRefPubMed
7.
Zhang Y, Zhu Y, Xiao M, Cheng Y, He D, Liu J, Xiang L, Gong L, Wang Z, Deng L, et al. The Long Non-coding RNA TMPO-AS1 Promotes Bladder Cancer Growth and Progression via OTUB1-Induced E2F1 Deubiquitination. Front Oncol. 2021;11:643163.CrossRefPubMedPubMedCentral
8.
Ashok C, Ahuja N, Natua S, Mishra J, Samaiya A, Shukla S. E2F1 and epigenetic modifiers orchestrate breast cancer progression by regulating oxygen-dependent ESRP1 expression. Oncogenesis. 2021;10(8):58.CrossRefPubMedPubMedCentral
9.
Wu Y, You Z, Xu M. Genetic Polymorphism of E2F1 Influences Susceptibility to Ovarian Cancer in a Chinese Population. Contrast Media Mol Imaging. 2022;2022:7808726.CrossRefPubMedPubMedCentral
10.
Fischer M, Schade AE, Branigan TB, Muller GA, DeCaprio JA. Coordinating gene expression during the cell cycle. Trends Biochem Sci. 2022;S0968-0004(22):00148-7:14.
11.
12.
Ren X, Wei X, Ding Y, Qi F, Zhang Y, Hu X, Qin C, Li X. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review. Onco Targets Ther. 2019;12:733–44.CrossRefPubMedPubMedCentral
13.
14.
Wang Q, Liu J, Cheang I, Li J, Chen T, Li Y, Yu B. Comprehensive Analysis of the E2F Transcription Factor Family in Human Lung Adenocarcinoma. Int J Gen Med. 2022;15:5973–84.CrossRefPubMedPubMedCentral
15.
Wang L, Yang X, Song Q, Fu J, Wang W, Du K, Chen S, Cao J, Huang R, Zou C. Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation. Front Pharmacol. 2021;12:617555.CrossRefPubMedPubMedCentral
16.
Mega S, Miyamoto M, Kaneko H, Ebihara Y, Takahashi R, Hashimoto H, Hase R, Murakami Y, Li L, Itoh T, et al. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis Esophagus. 2005;18:109–13.
17.
Xiao Wang PG. Meng Wang, Jing Liu, Jiaxiang Lin, Shule Zhang, Weiming Zhao, Jingwen Zhang, Wei Pan, Zeyu Sun, Feifei Sun, Chenghao Guo, Yiwei Zhao, Qingwei Wang: Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis. Am J Transl Res. 2017;9(5):2327–39.PubMedPubMedCentral
18.
Sulzyc-Bielicka V, Domagala P, Bielicki D, Safranow K, Rogowski W, Domagala W. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy. Pathol Oncol Res. 2016;22(3):601–8.CrossRefPubMed
19.
Kwon MJ, Nam ES, Cho SJ, Park HR, Shin HS, Park JH, Park CH, Lee WJ. E2F1 expression predicts outcome in Korean women who undergo surgery for breast carcinoma. Ann Surg Oncol. 2010;17(2):564–71.CrossRefPubMed
20.
Mans DA, Vermaat JS, Weijts BG, van Rooijen E, van Reeuwijk J, Boldt K, Daenen LG, van der Groep P, Rowland BD, Jans JJ, et al. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients. J Pathol. 2013;231(1):117–29.CrossRefPubMed
21.
Wang Q, An Y, Wang F, Zhang G, Zhang L, Dong H, Xin J, Li Y, Ji S, Guo X. OSchol: an online consensus survival web server for cholangiocarcinoma prognosis analysis. HPB (Oxford). 2021;23(4):545–50.CrossRefPubMed
22.
Zhang Y, Wang Z, Ma J, Huo J, Li Y, Wang Y, Chen H, Shan L, Ma X. Bioinformatics Identification of the Expression and Clinical Significance of E2F Family in Endometrial Cancer. Front Genet. 2020;11:557–188.
23.
Xiong M, Wang P, Pan B, Nie J, Wang S, He B: The diagnostic and prognostic values of microRNA-196a in cancer. Biosci Rep. 2021;41(1).
24.
Gao Y, Li H, Ma X, Fan Y, Ni D, Zhang Y, et al. ESaXZ: KLF6 suppresses metastasis of clear cell renal cell carcinoma via transcriptional repression of E2F1. Cancer Res. 2017;77(2):330–42.CrossRefPubMed
25.
Shen D, Gao Y, Huang Q, Xuan Y, Yao Y, Gu L, Huang Y, Zhang Y, Li P, Fan Y, et al. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis. Cancer Lett. 2021;514:48–62.CrossRefPubMed
26.
Gao Z, Shi R, Yuan K, Wang Y. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis. Tumour Biol. 2016;37(11):14979–87.CrossRefPubMed
27.
Liu Y, Yao Y, Liao B, Zhang H, Yang Z, Xia P, Jiang X, Ma W, Wu X, Mei C, et al. A positive feedback loop of CENPU/E2F6/E2F1 facilitates proliferation and metastasis via ubiquitination of E2F6 in hepatocellular carcinoma. Int J Biol Sci. 2022;18(10):4071–87.CrossRefPubMedPubMedCentral
28.
Min-Cheng Yu J-XL. Xiao-LuMa, Bo-Hu, Pei-Yao Fu, Hai-Xiang Sun, Wei-Guo Tang, Zhang-Fu Yang, Shuang-Jian Qiu, Jian Zhou, Jia Fan, & YangXu: Differential network analysis depicts regulatory mechanisms for hepatocellular carcinoma from diverse backgrounds. Future Oncol. 2019;15(34):3917–34.CrossRef
29.
Lin M, Liu Y, ChuanfengZhang,Central Laboratory, XiaokunDing,Chenxi Yang, QinjianKe, Zejun Fang, Jieyao Shi, Linfu Zhou, Zewei Ma, Ming Ye. E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation. Am J Cancer Res. 2019;9(2):285–99.PubMedPubMedCentral
30.
Fang ZJ, Yang H, Chen D, Shi XY, Wang QQ, Gong CJ, Xu X, Liu H, Lin M, Lin JX, et al. YY1 promotes colorectal cancer proliferation through the miR-526b-3p/E2F1 axis. Am J Cancer Res. 2019;9(12):2679–92.PubMedPubMedCentral
31.
Fang Z, Gong C, Yu S, Zhou W, Hassan W, Li H, Wang X, Hu Y, Gu K, Chen X, et al. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling. Cancer Lett. 2018;415:58–72.CrossRefPubMed
Metadata
Title
Prognostic role of E2F1 gene expression in human cancer: a meta-analysis
Authors
Jingjing Li
Wen Bi
Fang Lu
Bei Pan
Mengqiu Xiong
Lubanga Nasifu
Zhenlin Nie
Bangshun He
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10865-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway

Research

Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease

Research

Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting

Research

High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients

Research

Developing a predictive nomogram for colposcopists: a retrospective, multicenter study of cervical precancer identification in China

Research

MMP14 expression levels accurately predict the presence of extranodal extensions in oral squamous cell carcinoma: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits